Skip to main content
. 2022 Feb 8;18(2):e1009862. doi: 10.1371/journal.ppat.1009862

Fig 9. Chemically activating Rv1625c reduces Mtb pathogenesis in vivo.

Fig 9

Effect of V-59 treatment on bacterial burden and pathology in the lungs of BALB/c (A and B) or C3HeB/FeJ mice (C and D). In (A-D) mice were infected and treated with V-59, INH, or vehicle control. Data are from two independent experiments with 5 mice (A and B), or one experiment with 10 mice (C and D) per group. Outliers with CFUs below the infectious dose were excluded from the analyses (*P < 0.05, Mann-Whitney test). (E and F) Impact of mCLB073 treatment on bacterial burden (E) and pathology (F) in BALB/c mice infected and treated with the indicated doses of mCLB073, INH, or vehicle control (*P < 0.05, **P < 0.01, Kruskal-Wallis test and Dunn’s multiple comparisons test). Infections in (A-F) were by the intranasal route. Data are from one experiment with 10 mice per group. (G) Impact of mCLB073 treatment on bacterial burden in BALB/c mice infected by aerosol and treated with 5mg/kg mCLB073 or vehicle control. Data are from one experiment with 5 mice per group (*P < 0.05, Kruskal-Wallis test and Dunn’s multiple comparisons test). All data are shown as means ± SEM.